Skip to main content
Premium Trial:

Request an Annual Quote

Wellcome Trust to Boost Spending on Biomedical Research

NEW YORK (GenomeWeb News) – The Wellcome Trust today announced that it would increase its spending on biomedical research to nearly £4 billion ($7.86 billion) over the next five years.
 
The UK’s largest charity said that the increased funding — up from £2.5 billion over the last five years — would allow it to “respond flexibly to medical needs and scientific opportunities.”
 
The Trust said that a one-off additional spend of £500 million will be invested in large-scale biomedical projects worldwide including the next generation of large-scale genetic studies; major initiatives in neuroscience and mental health; a new medical center in London, called the UK Center for Medical Research and Innovation; the Health Innovation Challenge Fund, which is a partnership of the Department of Health and other programs to translate scientific discoveries into new treatments; and strengthening research capacity in Africa.
 
“This proposed extra spend will enable us to fund important research aimed at tackling some of the world’s major diseases,” Mark Walport, director of the Wellcome Trust, said in a statement.
 
The Wellcome Trust spent £520 million in 2006-2007. Among its accomplishments during that period was the publication of results from the Wellcome Trust Case Control Consortium, the largest ever study of the genetics behind common diseases. Findings from the research included genes implicated in diabetes, rheumatoid arthritis, coronary artery disease, and the first common gene linked to obesity.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.